Efficacy and Safety of Peginterferon Alfa-2a (40KD) Plus Ribavirin in Hepatitis C Patients with Advanced Fibrosis and Cirrhosis

AO Fatebenefratelli e Oftalmico, Milan, Italy.
Hepatology (Impact Factor: 11.19). 02/2010; 51(2):388-97. DOI: 10.1002/hep.23340
Source: PubMed

ABSTRACT The objective of this study is to determine the efficacy and safety of peginterferon alfa-2a (40 KD)/ribavirin in patients with advanced fibrosis. Data from 341 genotype 1/4 patients (99 with bridging fibrosis/cirrhosis) treated for 48 weeks and 1547 genotype 2/3 patients (380 with bridging fibrosis/cirrhosis) treated for 16 or 24 weeks enrolled in three randomized international studies were analyzed. Sustained virological response (SVR) rates decreased progressively from 60% in genotype 1/4 patients without advanced fibrosis to 51% in those with bridging fibrosis and 33% in those with cirrhosis (trend test P = 0.0028); and from 76% to 61% and 57%, respectively, in genotype 2/3 patients treated for 24 weeks (trend test P < 0.0001). Irrespective of genotype, patients without advanced fibrosis were more likely to have an earlier response to treatment that was associated with higher SVR rates and lower relapse rates during untreated follow-up. Among patients with or without a diagnosis of advanced fibrosis, rates of SVR and relapse were similar for patients with similar responses in the first 12 weeks. CONCLUSION: Compared with patients with less severe disease, SVR rates are significantly lower in patients with advanced fibrosis. However, irrespective of genotype and degree of fibrosis, the time to become hepatitis C virus (HCV) RNA undetectable was the strongest predictor of SVR.

Download full-text


Available from: Stephanos Hadziyannis, Sep 08, 2014
  • Source
    AIDS (London, England) 05/2015; 29(8):982-985. DOI:10.1097/QAD.0000000000000621 · 6.56 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hepatitis B and hepatitis C infections are important causes of end-stage liver disease and primary liver cancer. Successful antiviral treatment prior to the development of cirrhosis will prevent most of the morbidity and mortality associated with those infections. This can be achieved for a high proportion of patients. However, many patients present with end-stage liver disease and ongoing and clinically significant viral replication. Antiviral treatment of HBV can effect recovery of liver function and restores many patients to a state of well compensated cirrhosis. The antiviral treatment of end-stage HCV poses much greater challenges. Interferon remains an essential element of HCV antiviral treatment, but has reduced efficacy and significant toxicity at this stage of cirrhosis. Though yet to be evaluated in the setting of advanced liver disease, the development of direct acting antivirals for HCV offers hope for improved outcomes at this stage of cirrhosis.
    Gut 05/2012; 61 Suppl 1:i59-67. DOI:10.1136/gutjnl-2012-302076 · 13.32 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Peg-interferon-alpha-2a (PEG-IFN) has been used all over the world including Japan as the standard of care for chronic hepatitis C (CHC). PEG-IFN causes platelet count decrease, while CHC patients with compensated liver cirrhosis has low baseline of platelet. To use PEG-IFN more safely in the patients, we analyzed longitudinal platelet profile affected by PEG-IFN with a pharmacokinetic-pharmacodynamic model. Platelet count and serum PEG-IFN concentration obtained from Japanese clinical study on 40 patients were analyzed. Serum PEG-IFN concentration profile was fitted with an open 1-compartment model and the platelet profile was fitted with a turnover model. After the final model was fixed, the platelet profiles were simulated with various platelet baselines. The simulation revealed that according to PEG-IFN administration platelets decreased gradually and reached steady state within 12 weeks, and almost subjects would not have lower platelet count than the criteria for discontinuation of the treatment. Once administration was discontinued, platelets recovered up to the baseline within several weeks. In conclusion, platelet count was predicted to be about 30% (5(th)-95(th) percentiles in 1000 simulation: 11%-66%) decrease and to return to baseline value in 4 to 8 weeks after the last administration of PEG-IFN.
    Drug Metabolism and Pharmacokinetics 06/2012; 27(6). DOI:10.2133/dmpk.DMPK-11-RG-148 · 2.86 Impact Factor